Related Experiment Video
Updated: Jun 19, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
First Discovery of the Dual-Functional Inhibitor Targeting VEGFR/PDGFR/CA II for the Treatment of Neovascular
Xiaomeng Xiu1, Yulong Cheng1, Jiarao Wang1
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Liaoning, Shenyang 110016, China.
Abstract:
Neovascular glaucoma (NVG) seriously threatens visual, through elevated intraocular pressure (IOP) and intraocular neovascularization. At present, no clinical drug simultaneously lowers IOP and inhibits vascular growth. Moreover, to address the high invasiveness of intravitreal injection and the high systemic toxicity of oral administration, we ultimately discovered the first VEGFR/PDGFR/CA II dual-functional inhibitor H24 for treating NVG that can be administered through the subconjunctival injection. Compared with positive drugs Vorolanib and Acetazolamide, H24 exhibited better inhibitory activity against VEGFR2, PDGFRα/β and CA II enzymes. Moreover, H24 exhibited potent antiproliferative activity in VEGFR2-BAF3 cells and robust inhibition of angiogenesis in HUVECs. Furthermore, H24 also inhibited the formation of corneal neovascularization in rabbits through multiple signaling pathways. In acute and chronic glaucoma model, H24 significantly reduced the IOP of rabbits. Overall, these findings provided compelling evidence that H24 offers new perspectives in the treatment of NVG.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Diabetic Retinopathy
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...